Skip to main content
. 2021 May 6;30(8):1244–1253. doi: 10.1177/09612033211013898

Figure 1.

Figure 1.

(a) Plasma osteopontin (OPN) concentrations in healthy controls (n = 60) and the entire group of SLE patients (n = 60), as well as for the three SLE phenotypes of which each include 20 individuals. (b) CCA IMT of healthy controls (n = 60) and the entire group of SLE patients (n = 60), as well as for the three SLE phenotypes of which each include 20 individuals.

n.s. = not significant.